AP826A - Arysulfonylamino hydroxamic acid derivatives. - Google Patents

Arysulfonylamino hydroxamic acid derivatives. Download PDF

Info

Publication number
AP826A
AP826A APAP/P/1998/001191A AP9801191A AP826A AP 826 A AP826 A AP 826A AP 9801191 A AP9801191 A AP 9801191A AP 826 A AP826 A AP 826A
Authority
AP
ARIPO
Prior art keywords
aryl
heteroaryl
alkyl
carboxylic acid
aryloxy
Prior art date
Application number
APAP/P/1998/001191A
Other versions
AP9801191A0 (en
Inventor
Ralph Pelton Robinson
Kim Francis Mcclure
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9801191A0 publication Critical patent/AP9801191A0/en
Application granted granted Critical
Publication of AP826A publication Critical patent/AP826A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of the formula wherein R1, R2 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Description

ARYLSULFQNYLAMINO HYDROXAMIC ACID DERIVATIVES
The present invention relates to arylsulfonylamino hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (hereinafter NSAID'S) and analgesics for the treatment of arthritis, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, in the treatment of cancer.
This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor.
There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalloproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J. Leuk. Biol,, 52 (2): 244-248, 1992).
AP/P/ 9 8/011 91
Tumor necrosis factor is recognized to be involved in many infectious and auto30 immune diseases (W. Fiers, FEBS Letters. 1991, 285, 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et ai., Clinical Immunology and Immunopathology. 1992, 62 S11).
AP 0 0 0 8 2 6
-2The present invention relates to a compound of the formula
H0-NH
II
-CR1
I
-CR!
H
-N S\ // o Q or the pharmaceutically acceptable salts thereof, wherein
R' and R2 are each independently selected from (CT-C^alkyl, trifluoromethyl, trif I u oro met hyl (C,-C6) alkyl, (C,-Ce) alkyl (difiuoro methyl ene), (C, C3)alkyl(difluoromethylene(C1-C3)alkyl, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cg-C^ary^C,- a C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or R1 and R2 may be taken together to form a (C3C6)cycloalkyl or benzo-fused (C3-C6)cycloalkyl ring or a group of the formula
wherein n and m are independently 1 or 2 and X is CF2, S, O or NR3 wherein R3 is hydrogen, (CrCe)alkyl, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cg-C^arylCC^CgJalkyl, (C2CgjheteroarylfC^Cgjalkyl, (CT-C^alkylsulfonyl, (C6-C10)arylsulfonyi or acyl; and
Qis(C1-Ce)alkyl,(C6-C10)ary!,(Cg-C10)aryloxy(C6-C10)aryl,(C6-C10)aryf(C6-C10)aryl, (C6-Cl0)aryl(C6-C10)aryl(C1-Cg)alkyl, (Cs-C10)aryl(C2-C9)heteroaryl, (C6-Clo)aryloxy(C2C9)heteroaryl, (C2-C9)heteroaryl, (C2-C9)heteroaryl(C2-C9)heteroaryl, (C2-C9)heteroaryl(C6C10)aryl,(C1-C6)alkyl(C6-C10)aryl1(C,-C6)alkoxy(C6-C10)arylt(Ce-C,0)aryl(C1-Ce)alkoxy(CeC10)aryl, (Cg-C^aryiO^-Cgjalkoxy^-CgJalkyl, (C2-C9)heteroaryloxy(C6-C10)aryl, (C,Ce)alkyl(C2-C9)heteroaryl, (C1-C6)eilkoxy(C2-C9)heteroaryl, (Cg-C^aryl^-C/alkoxytC.,C9)heteroaryl, (C2-Cg)heteroaryloxy(C2-C9)heteroaryl, (Cg-C^Jaryloxy^-CgJalkyl, (C2C9)heteroaryloxy(C,-C6)alkyl, (Cl-Ce)alkyl(Ce-Clo)aryloxy(Ce-C1o)aryl, (C,-Ce)alkyl(C2C9)heteroaryloxy(C6-C10)aryl, (C1-Ce)alkyl(Ce-C10)aryloxy(C2-C9)heteroaryl, (Cr C6)alkoxy(Cg-C10)aryloxy(Cg-C10)aryl, (C1-Ce)alkoxy(C2-C9)heteroaryloxy(Cs-C10)aryl or (C,-Ce)alkoxy(Ce-C10)aryloxy(C2-Cg)heteroaryl wherein each aryl group is optionally substituted byfluoro, chloro, bromo, (C,-Ce)alkyl, (C^C^alkoxy orperfluoro^-C^alkyl.
AP/P/ 9 8/011 91
APO00826
-3The term ’alkyl, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
The term alkoxy, as used herein, includes O-alkyl groups wherein alkyl is 5 defined above.
The term aryl, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, trifluoromethyi, (C^CgJalkoxy, (Ce-C10)aryloxy, trifluoromethoxy, difluoromethoxy and (C,-Ce)aikyl.
The term heteroaryl, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyroyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazoiyl, thiazolyl, oxazolyi, benzthiazolyl br benzoxazolyl, optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, trifluoromethyi, (C,-C6)alkoxy, (CeC,0)aryloxy, trifluoromethoxy, difluoromethoxy and (C^-Cgjalkyl.
The term acyl, as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkyloxy and the terms alkyl or aryl are as defined above.
The term acyloxy, as used herein, includes O-acyl groups wherein acyl is defined above.
The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.
Preferred compounds of formula I include those wherein R1 and R2 are taken together to form a (C3-C6)cycloalkyl or benzo-fused (C3-C6)cycloalkyl ring or a group of the formula
AP/PZ 9 8/01191
AP ο Ο Ο 8 2 6
wherein η and m are independently 1 or 2 and X is CF2, S, O or NR3 wherein R3 is hydrogen, (C^CJalkyl, (Ce-C10)aryl, (C2-C9)heteroaryl, (Ce-C^aryKCT-CJalkyl, (C2CJheteroaryl^-CJalkyl, (C,-Ce)alkylsulfonyl, (Ce-C10)arylsuifonyl or acyl.
Other preferred compounds of formula I include those wherein R1 and R2 are 10 taken together to form a (C3-C6)cycloalkyl or benzo-fused (C3-Ce)cycloalkyl ring.
Other preferred compounds of formula I include those wherein Q is (C6-C10)aryl, (C6-C10)aryl(C6-C10)aryl, (C6-C10)aryloxy(Ce-C10)aryl, (C6-C10)aryloxy(C2-C9)heteroaryl, (C2-C9)heteroaryl, (C2-C9)heteroaryl(C2-C9)heteroaryi, (C6-C,0)aryl(C2-C9)heteroaryl, (C2C9)heteroaryl(C6-C10)aryl or (C2-C9)heteroaryloxy(C6-C10)aryl.
Other preferred compounds of formula I include those wherein Q is (CeC10)aryloxy(C6-C10)aryl.‘
Other preferred compounds of formula I include those wherein R1 and R2 are each independently (C,-Ce)alkyl.
More preferred compounds of formula I include those wherein R1 and R2 are 20 taken together to form a (C3-C6)cycloaikyl or benzo-fused (C3-C6)cycloalkyl ring or a group of the formula
AP/P/ 98/011 91 wherein n and m are independently 1 or 2 and X is CF2, S, O or NR3 wherein R3 is hydrogen, (C^CJalkyl, (C6-C10)aryl, (C2-C9)heteroaryl, (Cg-C^aryl^-CJalkyl, (C2CJheteroaryKC^CJalkyl, (C^CJalkylsulfonyl, (Ce-C10)arylsulfonyl or acyl; and Q is (Ce30 C10)aryl, (C6-C10)aryl(Ce-C10)aryl, (Ce-C10)aryloxy(C6-C10)aryl, (C6-C10)aryloxy(CrC9)heteroaryl, (C2-C9)heteroaryl, (C2-C9)heteroaryl(C2-C9)heteroaryl, (Ce-C10)aryl(C2C9)heteroaryl, (C2-C9)heteroaryl(Ce-C10)aryl or (C2-C9)heteroaryloxy(C6-C10)aryl.
AP Ο Ο Ο 8 2 6
-5More preferred compounds of formula I include those wherein R1 and R2 are taken together to form a (C3-Ce)cycloalkyl or benzo-fused (C3-Ce)cycloalkyl ring; and Qis (C6-C,0)aryl, (C6-C10)aryl(Ce-C10)aryl, (Ce-C,0)aryloxy(Ce-C10)aryl, (Ce-C10)aryloxy(C2C9)heteroaryl, (C2-C9)heteroaryl, (C2-C9)heteroaryl(C2-C9)heteroaryl, (Ce-C10)aryl(C25 C9)heteroaryl, (C2-C9)heteroaryl(Ce-C10)aryl or (C2-C9)heteroaryloxy(Ce-C10)aryl.
More preferred compounds of formula I include those wherein R1 and R2 are each independently (C^C^alkyl; and Q is (Ce-C10)aryl, (Ce-C10)aryl(Ce-C10)aryl, (CeC,0)aryloxy(Ce-C10)aryl, (C6-C10)aryloxy(C2-C9)heteroaryl, (C2-C9)heteroaryl, (C2C9)heteroaryl(C2-C9)heteroaryl, (C6-C10)aryl{C2-C9)heteroaryI, (C2-C9)heteroaryl(Ce10 C10)aryl or (C2-C9)heteroaryloxy(C6-C10)aryl.
More preferred compounds of formula I include those wherein R1 and R2 are each independently (C,-C6)alkyl; and Q is (C6-C10)aryloxy(Ce-C10)aryl.
Specific preferred compounds of formula I include the following:
3- [4-(4-Fluorophenoxy)benzenesulfonylamino]azetidine-3-carboxylic acid hydroxyamide;
4- [4-(4-Fluorophenoxy)benzenesulfonylamino]piperidine-4-carboxylic acid hydroxyamide;
-[4-(4-Fluorophenoxy)benzenesulfonylamino]cyclopropane-1 -carboxylic acid hydroxyamide;
1 -[4-(4-Chlorophenoxy)benzenesulfonylamino]cyclopropane-1 -carboxylic acid hydroxy amide;
-[4-(4-Fluorophenoxy)benzenesulfonylamino]cyclobutane-1 -carboxylic acid hydroxy amide;
-[4-(4-Chlorophenoxy)benzenesulfonylamino]cyclobutane-1 -carboxylic acid hydroxyamide;
-[4-(4-Fluorophenoxy)benzenesulfonylamino]cyclopentane-1 -carboxylic acid hydroxyamide;
-[4-(4-Fluorophenoxy)benzenesulfonylamino]cyclohexane-1 -carboxylic acid hydroxyamide;
2-[4-(4-Fluorophenoxy)benzenesulfonylamino]-N-hydroxy-2-methylpropionamide;
2-[4-(4-Chlorophenoxy)benzenesulfonylamino]-N-hydroxy-2-methyl-propionamide;
N-Hydroxy-2-methyl-2-(5-pyridin-2-ylthiophene-2-sulfonylamino)propionamide;
AP/P/ 98/01191
APOΟ 08 2 6
-61 -(5-Pyridin-2-yl-thiophene-2-sulfonylamino)cyclopentane-1 -carboxylic acid hydroxyamide;
-(4,-Fluorobiphenyl-4-sulfonylamino)cyclopropane-1 -carboxylic acid hydroxyamide;
1 -(4'-Fluorobiphenyl-4-siilfonylamino)cyclobutane-1 -carboxylic acid hydroxyamide;
-(4'-Fluorobiphenyl-4-sulfonylamino)cyclopentane-1 -carboxylic acid hydroxy amide;
2-(4-Methoxybenzenesufonylamino)indan-2-carboxylic acid hydroxyamide; and
2-[4-(4-Fluorophenoxy)benzenesulfonylamino]-indan-2-carboxylic acid hydroxy amide.
The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable carrier.
The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in combination with standard NSAID'S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of
AP/P/ 98/01191
AP 0 0 0 8 2 6
-7formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition.
The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated R1, R2 and Q in the reaction Schemes and the discussion that follow are defined as above.
Preparation A
AP/P/ 9 8/01191
Vi i
J^GISTRAR OF PAINTS I
AND TRADE MARKS f
JANWdg j ~ PO.tOYCV’?? ί
AP 0 0 0 8 2 6
-8Scheme 1
I
IV
AP/P/ 9 8/01 1 9 1
AP Ο Ο Ο 8 2 6
-9Ιη Reaction 1 of Preparation A, an amino acid of formula III is treated with benzyl alcohol and an acid of the formula HX, wherein X is preferably 4toluenesulfonate, in an inert solvent, such as benzene or toluene (toluene preferred) to obtain the corresponding benzyl ester acid salt of formula V. The reaction is normally carried out for a time period between about 1 hour to about 24 hours, at the boiling temperature of the solvent used. The water formed during the progress of the reaction is normally collected in a Dean-Stark trap.
In Reaction 2 of Preparation A, the compound of formula V is converted to the corresponding compound of formula VI by reacting V with a reactive functional derivative of a sulfonic acid (QSO2OH), such as the sulfonyl chloride (QSO2CI), in the presence of a base, such as sodium hydroxide or triethylamine, and a solvent, such as methylene chloride, tetrahydrofuran, dioxane, water or acetonitrile, preferably a mixture of dioxane and water. The reaction mixture is stirred at a temperature between about 0°C to about 50°C, preferably at room temperature, for a time period between about
10 minutes to about 2 days, preferably about 60 minutes.
In Reaction 3 of Preparation A, the intermediate compound of formula VI is hydrogenolyzed to provide the intermediate of formula II. The reaction is carried out at in a solvent, such as ethanol, under an atmosphere of hydrogen (preferably at 3 atmospheres pressure) using a catalyst such as 10% palladium on activated carbon.
The reaction mixture is normally agitated at room temperature for a time period between about 30 minutes to about 24 hours, preferably about 1.5 hours.
In reaction 1 of Scheme 1, the amino acid compound offormula III is converted to the corresponding compound of formula II by reacting III with a reactive functional derivative of a sulfonic acid of the formula QSO2OH, wherein Q is as defined above, such as the sulfonyl chloride (QSO2CI), in the presence of a base, such as sodium hydroxide or triethylamine, and a polar solvent such as tetrahydrofuran, dioxane, water or acetonitrile, preferably a mixture of dioxane and water. The reaction mixture is stirred at a temperature between about 0°C to about 50°C, preferably at room temperature, for a time period between 10 minutes to about 2 days, preferably about 60 minutes.
In reaction 2 of Scheme 1, the carboxylic acid of formula II is converted to the hydroxamic acid compound offormula I by treating II with 1 -(3-dimethylaminopropyl)-3ethylcarbodiimide and 1-hydroxybenztriazoie in a polar solvent, such as N,Ndimethylformamide, followed by the addition of hydroxylamine to the reaction mixture
AP/PI 9 8/01191
AP ο Ο ο 8 2 6
-10after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxyiamine is preferably generated in situ from a salt form, such as hydroxylamine hydrochloride, in the presence of a base, such as triethylamine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxyl group is protected as a tert-butyl, benzyl, allyl or 2-trimethylsilylethyl ether, may be used in place of hydroxylamine or a hydroxylamine salt. Removal of the hydroxyl protecting group is carried out by hydrogenolysis for a benzyl protecting group (5% palladium on barium sulfate is the preferred catalyst) or treatment with a strong acid, such as trifluoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) pa!ladium(ll)chloride. The 2-trimethylsilylethyl ether may be removed by reaction with a strong acid such as trifluoroacetic acid or by reaction with a fluoride source such as boron trifluoride etherate. The reaction of II with hydroxylamine, a salt of hydroxylamine, a protected derivative of hydroxylamine or a salt of a protected derivative of hydroxylamine may also be carried out the presence of (benztriazol-1-yloxy)triS(dimethylamino)-phosphoniumhexafluorophosphateandabase such as triethylamine in an inert solvent, such as methylene chloride. The reaction mixture is stirred at a temperature between about 0°C to about 50°C, preferably room temperature, for a time period between about 1 hour to about 3 days, preferably about
1 day. The preferred procedure for converting compound II to compound I is to react
II with O-benzylhydroxylamine hydrochloride in the presence of (benztriazol-1 yloxy)tris(dimethylamino)phosphonium hexafluorophosphate and triethylamine using methylene chloride as solvent. Subsequent removal of the O-benzyl protecting group to afford a compound of formula I is then carried out by hydrogenolysis under 3 atmospheres hydrogen at room temperature using 5% palladium on barium sulfate as catalyst. The preferred solvent is methanol. The reaction time may vary from about 1 hour to about 5 hours (3.5 hours preferred).
In certain instances it is preferred to obtain the compound of formula I by reaction of hydroxylamine, a salt of hydroxylamine, a protected derivative of hydroxylamine or a salt of a protected derivative of hydroxylamine with an activated ester of formula IV, as shown in Reaction 3 of Scheme 1. The reaction is carried out in an inert solvent, such as Ν,Ν-dimethyl-formamide at a temperature ranging from about room temperature to about for a time period of f (&GISTRA.R Or PATENTS I AMD TRADE MARKS } .29JANWSC j
I · l
AP/P/ 9 8/01191
AP Ο Ο Ο 8 2 6
-11about 1 hour to about 2 days. If a protected derivative of hydroxylamine or a salt of a protected derivative of hydroxylamine is used, removal of the protecting group is carried out as described above. The activated ester derivative of formula IV is obtained by treatment of the compound of formula II with (benztriazol-1 -yloxy)tris(dimethylamino)5 phosphonium hexafluorophosphate and a base such as triethylamine in an inert solvent, such as methylene chloride (Reaction 4, Scheme 1). The reaction mixture is stirred at a temperature between about 0°C to about 50°C, preferably room temperature, for a time period between about 1 hour to about 3 days, preferably about 1 day.
Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris(hydroxymethyl)-methylammonium slats.
Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are aiso possible provided a basic group, such as pyridyl, constitutes part of the structure.
The ability of the compounds of formula I or their pharmaceutically acceptable salts (hereinafter also referred to as the compounds of the present invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests.
Biological Assay
Inhibition of Human Collagenase (MMP-1)
Human recombinant collagenase is activated with trypsin using the following ratio: 10 /zg trypsin per 100 /zg of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 /zg/10 pg trypsin) of soybean trypsin inhibitor is added.
10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:
mM--> 120 μΜ---> 12 μΜ-> 1.2 μΜ-> 0.12 μΜ
16110/86 ,'d/dV
APO 00 8 2 6
-12Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfiuor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.
Collagenase is diluted to 400 ng/ml and 25 μ\ is then added to appropriate wells of the microfiuor plate. Final concentration of collagenase in the assay is 100 ng/ml.
Substrate (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) is made as a5 mM stock in dimethyl sulfoxide and then diluted to 20 μΜ in assay buffer. The assay is initiated by the addition of 50 μΙ substrate per well of the microfiuor plate to give a final concentration of 10μΜ.
Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.
Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC50 values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100). IC50's are determined from the concentration of inhibitor that gives a signal that is 50% of the control.
If IC50's are reported to be <0.03 μΜ then the inhibitors are assayed at concentrations of 0.3 μΜ, 0.03 μΜ, 0.03 μΜ and 0.003 μΜ.
Inhibition of Gelatinase (MMP-2)
Inhibition of gelatinase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)His-Ala-Lys(NMA)-NH2 substrate (10 μΜ) under the same conditions as inhibition of human collagenase (MMP-1).
θθ 72kD gelatinase is activated with 1 mM ΑΡΜΑ (p-aminophenyl mercuric acetate) for Ί5 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give
98/01191
APO00826
-13final concentrations in the assay of 30 μΜ, 3 μΜ, 0.3 μΜ and 0.03 μΜ. Each concentration is done in triplicate.
Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours.
IC50's are determined as per inhibition of human collagenase (MMP-1). If IC50's are reported to be less than 0.03 μΜ, then the inhibitors are assayed at final concentrations of 0.3 μΜ, 0.03 μΜ, 0.003 μΜ and 0.003 μΜ.
Inhibition of Stromelysin Activity (MMP-3)
Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., Spectrophotometric Assay for Vertebrate Collagenase, Anal. Biochem. 147. 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-GlySCH[CH2CH(CH3)2]CO-Leu-Giy-OC2H5] yields a mercaptan fragment that can be monitored in the presence of Ellman's reagent.
Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μΙ of a 10 mg/ml trypsin stock per 26 μg of stromelysin. The trypsin and stromelysin are incubated at 37°C for 15 minutes followed by 10 μΙ of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity.
Assays are conducted in a total volume of 250 μΙ of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter plates. Activated stromelysin is diluted in assay buffer to 25 μg/ml. Ellman’s reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μΙ per well yielding at 1 mM final concentration.
mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μ\- to the appropriate wells yields final concentrations of 3 μΜ, 0.3 μΜ, 0.003 μΜ, and 0.0003 μΜ. All conditions are completed in triplicate.
A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μΙ to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.
IC50 values were determined in the same manner as for collagenase.
AP/F/ 9 8/01191
AP Ο Ο Ο 826
-14Inhibition of MMP-13
Human recombinant MMP-13 is activated with 2mM ΑΡΜΑ (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5mM calcium chloride, 20μΜ zinc chloride,
0.02% brij). Twenty-five microiiters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.
mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microiiters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μΜ, 3μΜ, 0.3 μΜ, and 0.03 μΜ.
Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) is prepared asfor inhibition of human collagenase (MMP-1) and 50 μΙ is added to each well to give a final assay concentration of 10 μΜ. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.
Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.
IC50‘s are determined as per inhibition of human collagenase (MMP-1). If IC5Q's are reported to be less than 0.03 μΜ, inhibitors are then assayed at final concentrations of 0.3 μΜ, 0.03 μΜ, 0.003 μΜ and 0.0003 μΜ.
Inhibition of TNF Production
The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following in vitro assay:
Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 10® /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.
AP/PZ 9 8/01191
APO 0 0 8 2 6
-15·<>
180μ of the cell suspension was aliquoted into flate bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 200//I. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO2 incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNFa using the R&D ELISA Kit.
For administration to mammals, including humans, for the inhibition of matrix metalioproteinases or the production of tumor necrosis factor (TNF), a variety of conventional routes may be used including orally, parenterally and topically. In general, the active compound will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
The compounds of the present invention can be administered in a wide variety of different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. In the case of animals, they are
AP/P/ 9 8/01191
AP Ο Ο Ο 8 2 6
-16advantageously contained in an animal feed or drinking water in a concentration of 55000 ppm, preferably 25 to 500 ppm.
For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared.
Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to
3 divided doses.
The present invention is illustrated by the following examples, but it is not limited to the details thereof.
Preparation A
4-(4-Fluorophenoxy)benzenesulfonyl chloride
Chlorosulfonic acid (26 mL, 0.392 mole) was added dropwise to ice-cooled 4fiuorophenoxybenzene (36.9 grams, 0.196 mole) with mechanical stirring. When addition was complete, the mixture was stirred at room temperature for 4 hours. The mixture was then poured into ice water. The product, 4-(4-fluorophenoxy)benzenesulfonylchloride (18.6 grams, 33%) was collected by filtration and dried in the air.
25 Preparation B
Sodium 4-(3-methylbutoxy)benzenesulfonate
A solution of 4-hydroxybenzenesulfonic acid (10.0 grams, 43.1 mmole) and sodium hydroxide (3.3 grams, 83 mmole) in water (40 mL) was mixed with a solution of 1-iodo-3-methylbutane (11.3 mL, 86.4 mmole) in isopropanol (60 mL) and the resulting mixture was heated at reflux for 2 days. The isopropanol was removed by evaporation under vaccuum. The titled compound, 10.0 grams (87%), was collected by filtration washing with isopropanol. j»·*®*»-*·.
AP/P/ 9 8/01191
AP Ο Ο Ο 8 2 6
-17Preparatlon C
4-(3-Methylbutoxv)benzenesulfonyl chloride
A mixture of sodium 4-(3-methylbutoxy)benzenesulfonate (2.5 grams, 9.4 mmole), thionyl chloride (10 mL), and 5 drops of Ν,Ν-dimethylformamide was heated at reflux for 5 hours. After cooling, the excess thionyl chloride was evaporated and the residue was taken up in ethyl acetate. The solution was cooled in an ice bath and water was added. The organic phase was separated and washed with water and brine. After drying over sodium sulfate, the solvent was evaporated to afford the titled compound as an oil, 2.34 grams (95%).
Preparation D
Sodium 4-(2-cyclopentvlethoxv)benzenesulfonate
A solution of 4-hydroxybenzenesulfonic acid (6.5 grams, 28.2 mmole) and sodium hydroxide (2.2 grams, 55 mmole) in water (15 mL) was mixed with a solution of 2-(bromoethyi)cyclopentane (15.0 grams, 84.7 mmole) in isopropanol (40 mL) and the resulting mixture was heated at reflux for 2 days. The isopropanol was removed by evaporation under vaccuum. The titled compound, 4.7 grams (57%), was collected by filtration washing with isopropanol.
Preparation E
4-(3-Methylbutoxv)benzenesulfonyl chloride
A mixture of sodium 4-(2-cyclopentylethoxy)-benzenesulfonate (2.5 grams, 8.6 mmole), thionyl chloride (15 mL), and a few drops of Ν,Ν-dimethylformamide was heated at reflux for 5 hours. After cooling, the excess thionyl chloride was evaporated and the residue was taken up in ethyl acetate. The solution was cooled in an ice bath and water was added. The organic phase was separated and washed with water and brine. After drying over sodium sulfate, the solvent was evaporated to afford the titled compound as an oil, 2.24 grams (90%).
Preparation F
4*-Fluorobiphenvlsulfonvl chloride
Chlorosulfonic acid (8.7 mL, 0.13 mole) was added dropwise to 4-fIuorobiphenyl (10.2 grams, 59 mmol) while sirring in an ice bath. Stirring was continued with ice cooling for 0.5 hours and then the reaction mixture was poured onto ice. The resulting white precipitate was collected by filtration and dissolved in chloroform. The chloroform solution was washed wHh water and brine, dried over magnesium sulfate and
AF.T,' 3 8/01191
ΑΡ ο ο 0 8 2 6
-18concentrated to afford a white solid. The desired product, 4'-fluorobiphenyisulfonyl chloride (4.3 grams, 27%), was separated from 4'-fluorobiphenyIsulfonic acid (an unwanted side product) by crystallization of the latter from ethyl acetate and crystallization of the remaining material from hexane.
Preparation G
Sodium 4-(4-fluorobenzyloxv)benzenesulfonate
To a solution of 4-hydroxybenzenesuifonic acid (5.13 grams, 22.1 mmole) in 1N aqueous sodium hydroxide solution (23 mL) was added a solution of 4fluorobenzylbromide (3.3 mL, 26.5 mmole) in ethanol (20 mL). The resulting mixture was heated at reflux for 2 days. Upon cooling and standing, a white solid precipitated. The precipitated product, sodium 4-(4-fluorobenzyloxy)benzenesulfonate, 4.95 grams (74%) was collected by filtration washing with ethyl acetate and diethyl ether.
Preparation H
4-(4-Fluorobenzvloxy)benzenesulfonvl chloride
To a slurry of sodium 4-(4-fluorobenzyloxy)benzenesulfonate (0.5 grams, 1.64 mmole), in methylene chloride (5 mL) was added phosphorus pentachloride (275 mg, 1.31 mmole). The resulting mixture was heated at reflux for 7 hours. After cooling in an ice bath and quenching with water (15 mL), the mixture was extracted with ethyl acetate. The organic phase was washed brine, dried over sodium sulfate, and concentrated to afford 4-(4-fluorobenzyloxy)benzenesulfonyl chloride a white solid (130 mg, 26%).
Preparation I
4-(4-Chlorophenoxv)benzenesulfonyl chloride
Chlorosulfonic acid (9.7 mL, 0.147 mole) was added dropwise to 4chlorophenoxybenzene (12.6 mL, 73.4 mmole) at room temperature with stirring. When addition was complete, the mixture was stirred at room temperature for 1 hour and then poured into ice water. The solid was collected by filtration, dried in the air, and recrystallized from petroleum ether and ethyl acetate to give 4-(4chlorophenoxy)benzenesulfonylchloride (7.43 grams, 33%).
AP/P/ 9 8/01191
REGISTRAR OP PATENTS AND TRADE MARKS
2R JAN
PC 1 Τ 7A
AP ο Ο Ο 8 2 6
-19Example 1
1-(4-Methoxvbenzene8ulfonvlamino)cvclopentane-1-carboxvllcacidhvdroxyamide (A) To a solution of 1-aminocyclopentane-1-carboxylic acid (6.0 grams, 46.5 mmole) and triethylamine (14 mL, 100 mmole) in dioxane (90 mL) and water (90 mL) was added 4-methoxybenzenesulfonyl chloride (10.6 grams, 51.3 mmole). The resulting mixture was stirred at room temperature for 4 hours, acidified with aqueous 1N hydrochloric acid solution, and extracted twice with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried over magnesium sulfate and concentrated to leave a tan solid which was triturated with chloroform to afford 1-(410 methoxybenzenesulfonylamino)-cyclopentane-1 -carboxylic acid as a white solid, 5.42 grams (39%).
(B) To a solution of 1-(4-methoxybenzenesulfonylamino)cyclopentane-1carboxylic acid (4.65 grams, 15.2 mmole) and triethylamine (2.5 mL, 17.9 mmole) in methylene chloride (120 mL) was added (benzotriazol-1 15 yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (7.4 grams, 16.3 mmole).
The resulting mixture was stirred at room temperature for 2.5 days. The solvent was evaporated and the residue was taken up in ethyl acetate. The solution was washed successively with aqueous 0.5 N hydrochloric acid solution, water and brine. After drying over magnesium sulfate, the solvent was evaporated to afford 1-(420 methoxybenzenesulfonylamino)cyclopentane-carboxylic acid benzotriazol-1 -yl ester as a yellow solid. This was dissolved in N,N-dimethyiformamide (120 mL) and to the resulting solution was added diisopropylethylamine (5.3 mL, 30 mmole) and Obenzylhydroxylamine hydrochloride (3.2 grams, 20 mmole). The mixture was heated in an oil bath at 50°C for 20 hours. The solvent was evaporated and ethyl acetate was added. The mixture was filtered to collect a white solid. The filtrate was washed successively with aqueous 0.5 N hydrochloric acid solution, aqueous saturated sodium bicarbonate solution and brine. Upon evaporation of the solvent, a solid was obtained . which was combined with that isolated by filtration and triturated with ethyl acetate to afford 1 -(4-methoxybenzenesulfonylamino)cyclopentane-1 -carboxylic acid benzyloxyamide as a white solid, 2.92 grams (47%).
. (C) A solution of 1 -(4-methoxybenzenesulfonyiamino)cyclopentane-1 -carboxylic acid benzyloxyamide (1.50 grams, 3.71 mmole) in methanol (200 mL) was treated with
5% palladium on barium sulfate (0.75 grams) and hydrogenated at 3 atmospheres
I 6 U 0 / 8 6 IdidV
AP Ο Ο ο 8 2 6
-20pressure for 3.5 hours in a Parr shaker. The catalyst was removed by passage through a 0.45 pm nylon filter and the filtrate was concentrated to afford 1-(4methoxybenzenesulfonylamino)-cyclopentane-1-carboxylic acid hydroxyamide_as a white solid, 1.13 grams (97%). MS: 313 (M-1).
The titled compounds of Examples 2-8 were prepared by a method analogous to that described in Example 1 using the reagents indicated.
Example 2
1-(4-Methoxvbenzenesulfonvlamino)cyclohexane-1 -carboxylic acid hydroxyamide.
-Aminocyclohexane-1 -carboxylic acid; 4-methoxybenzenesulfonyl chloride. MS:
327 (M-1).
Example 3
-i4-(4-Fluorophenoxv)benzenesulfonvlaminolcyclopentane-1 -carboxylic acid hydroxyamide
-Aminocyclopentane-1 -carboxylic acid; 4-(4-fluorophenoxy)benzenesulfonyl chloride. MS: 393 (M-1). Analysis calculated for C18H19FN205S.0.25 H2O: C 54.19, H 4.93, N 7.02. Found: C 54.20, H 5.13, N 7.08.
Example 4
1-r4-(4-Fluorophenoxy)benzenesulfonylaminoTcyclohexane-1-carboxylic acid hydroxyamide
1-Aminocyclohexane-1-carboxylic acid; 4-(4-fluorophenoxy)benzenesulfonyl chloride. Recrystallized from chloroform. MP: 174°C; MS: 407 (M-1).
Example 5 ~l-r4-(4-Fluorophenoxv)benzenesulfonylamino1cvclopropane-1-carboxylic acid hydroxyamide
1-Aminocyclopropane-1 -carboxylic acid; 4-(4-fluorophenoxy)benzenesulfonyl chloride. MP: 184°C; MS 365 (M-1); Analysis calculated for CieH15FN2O5S: C 52.45, H 4.13, N 7.65. Found: C 52.20, H 4.34, N 7.44.
Example 6
-(4,-Fluorobiphenyl-4-sulfonvlamino)cvclopentane-1 -carboxylic acid hydroxyamide
1-Aminocyclopentane-1-carboxylic acid; 4'-fluorobiphenylsulfonyl chloride.
Recrystallized from chloroform. MP 159 °C; MS: 377 (M-1).
AP/P/ 9 8/01191
AP Ο Ο Ο 8 2 6
-21Example 7
1-f4-(4-Fluorophenoxv)benzenesulfonvlamino1cyclobutane-1-carboxylic acid hydroxyamide
-Aminocyclobutane-1 -carboxylic acid; 4-(fluorophenoxy)benzenesulfonyl 5 chloride. MS: 379 (M-1).
Example 8
1-r4-(4-Fluorobenzvloxv)benzenesulfonvlaminolcyclopropanecarboxvlic acid hydroxyamide
-Aminocyclopropane-1 -carboxylic acid; 4-(4-fluorobenzyloxy)benzenesulfonyl chloride. MS: 379 (M-1).
Example 9
N-Hvdroxv-2-(4-methoxybenzenesulfonvlamino)-2-methvlpropionamide (A) A solution of 2-amino-2-methylpropionic acid benzyl ester hydrochloride (12.0 grams, 52.2 mmole) and 4-methoxybenzenesulfonylchloride (11.9 grams, 57.6 mmole) in dioxane (100 mL) and water (100 mL) was cooled in an ice bath. Triethylamine (18.2 mL, 0.13 mole) was then added. The ice bath was removed and the reaction mixture was allowed to stir at room temperature for 2 days. The solvents were removed under vacuum and the residue was taken up in ethyl acetate and water. The aqueous layer was separated and extracted twice with ethyl acetate. The combined organic layers were washed with aqueous saturated sodium bicarbonate solution, aqueous 1 N hydrochloric acid solution, and brine. After drying over sodium sulfate, the solvent was evaporated to leave a yellow oil (19.3 grams) a portion of which (10 grams) was chromatographed on silica gel eluting with 3:7 ethyl acetate/hexane to afford, after recrystallization from ethyl acetate/hexane, 2-(425 methoxybenzenesulfonylamino)-2-methylpropionic acid benzyl ester_as a white solid, 6.59 grams (67%).
(B) A solution of 2-(4-methoxybenzenesulfonyiamino)-2-methylpropionic acid benzyl ester (1.5 grams, 4.13 mmole) in ethanol (80 mL) was treated with 10% palladium on carbon (0.17 grams) and hydrogenated at 3 atmospheres pressure for 1.5 hours in a Parr shaker. The catalyst was removed by passage through a 0.45 μτη nylon filter and the filtrate was concentrated to afford 2-(4-methoxybenzenesulfonylamino)-2methylpropionic acid as a white solid, 1.09 grams (96%).
110/86 :2,'dV
AP Ο Ο Ο 8 2 6
-22(C) A solution of 2-(4-methoxybenzenesulfonylamino)-2-methyipropionic acid (1.08 grams, 3.95 mmole) in methylene chloride (120 mL) was cooled in an ice bath. Triethylamine (2.2 mL, 15.8 mmole), (benzotriazol-l-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (2.6 grams, 5.88 mmole) and O5 benzyihydroxylamine hydrochloride (0.95 grams, 5.95 mmole) were subsequently added. The resulting mixture was stirred at room temperature for 16 hours. The solvent was evaporated and the residue was taken up in ethyl acetate. The solution was washed successively with aqueous 1 N hydrochloric acid solution, aqueous saturated sodium bicarbonate solution, water and brine. After drying over sodium sulfate, the solvent was evaporated to afford an oil from which the desired product, Nbenzyloxy-2-(4-methoxybenzenesulfonylamino)-2-methyl-propionamide (1.41 grams, 95%), a white solid, was obtained by chromatography on siiica gel eluting with 1:2 ethyl acetate/hexanes.
(D) A solution of N-benzyloxy-2-(4-methoxybenzenesulfonylamino)-2-methyl15 propionamide (1.40 grams, 3.70 mmole) in methanol (80 mL) was treated with 5% palladium on barium sulfate (0.75 grams) and hydrogenated at 3 atmospheres pressure for 1.5 hours in a Parr shaker. The catalyst was removed by passage through a 0.45 //m nylon filter and the filtrate was concentrated to afford N-hydroxy-2-(4-methoxybenzenesulfonylamino)-2-methylpropionamide as a white solid, 1.06 grams (100%).
MP: 122-125°C. MS: 289 (M+1): Analysis calculated for CnHieN2O5S: C, 45.82; H, 5.59; N, 9.72; Found: C, 45.88; H, 5.60; N, 9.69.
The titled compounds of Examples 10-12 were prepared by a method analogous to that described in Example 9 using the reagents indicated.
Example 10 25 2-f4-(4-Fiuorophenoxy)benzenesulfonylamino1-N-hvdroxv-2-methvl-propionamide
2-Amino-2-methylpropionicacid benzyl esterhydrochloride; 4-(4-fluorophenoxy)benzenesulfonyl chloride. MP: 133-134°C. MS: 369 (M+1), Analysis calculated for C,eH17FN2O5S: C, 52.17; H, 4.65; N, 7.60; Found: C, 52.21; H, 4.83; N, 7.80.
Example 11 33 N-Hvdroxv-2-methvl-2-r4-(3-methvlbutoxv)benzenesulfonvlamino]-propionamide 2 Amino-2-methylpropionic acid benzyl ester hydrochloride; 4-(3-methylbutoxy)benzenesulfonyl chloride. Recrystailized from ethyl acetate/hexane. MP 126.5-128°C.
CO £
CU <
Τ 20 Ο
ΑΡ ο ο Ο 8 2 6
-23MS: 343 (Μ-1), Analysis calculated for C15H24N2O5S: C, 52.31; H, 7.02; N, 8.13; Found: C, 52.30; H, 7.07; N, 8.16.
Example 12
2-f4-(2-Cvclopentvlethoxv)benzenesulfonviamino1-N-hvdroxv-2-methylpropionamide
2-Amino-2-methylpropionic acid benzyl ester hydrochloride; 4-(2cyclopentylethoxy) benzenesulfonyl chloride. Recrystallized from ethyl acetate/hexane. MP 126-127°C. MS: 369 (M-1). Analysis calculated for C17H26N2O5S: C 55.12, H 7.07, N 7.56. Found: C 55.46, H 7.09, N 7.38.
Example 13
N-Hvdroxv-2-methvl-2-(5-pvridin-2-vlthiophene-2-sulfonyIamino)propionamide (A) To a solution of 2-amino-2-methylpropionic acid (2.0 grams, 19.4 mmole) in 1 N aqueous sodium hydroxide solution (45 mL) and dioxane (45 mL) was added 5pyridin-2-ylthiophene-2-sulfonyl chloride (8.41 grams, 32.4 mmole). The resulting mixture was stirred at room temperature for 16 hours. Additional 1 N aqueous sodium hydroxide solution (45 mL) was added to the reaction mixture which was then extracted with diethyl ether. The organic extracts were discarded. The aqueous layer was acidified with 1 N hydrochloric acid solution and extracted with ethyl acetate. The ethyl acetate fractions were washed with brine, dried over magnesium sulfate and concentrated to afford 2-methyl-2-(5-pyridin-2-ylthiophene-2-sulfonylamino)propionic acid as a white solid (2.18 grams, 34%).
(B) To a solution of 2-methyl-2-(5-pyridin-2-ylthiophene-2-sulfonylamino)propionic acid (1.60 grams, 4.91 mmole) in methylene chloride (160 mL) was added triethylamine (2.3 mL, 16.5 mmole), (benzotriazol-l-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (2.4 grams, 5.41 mmole) and 0-(2trimethylsilylethyl)hydroxylamine hydrochloride (0.92 grams, 5.41 mmole). The resulting mixture was stirred at room temperature for 16 hours. The solvent was evaporated and the residue was taken up in ethyl acetate. The solution was washed with water, aqueous saturated sodium bicarbonate solution, and brine. After drying over magnesium sulfate, the solvent was evaporated to afford a white foam from which the desired product, 2-methyl-2-(5-pyridin-2-ylthiophene-2-sulfonylamino)-N-(2trimethylsilanylethoxy)-propionamide (220 mg, 10%), a white solid, was isolated by chromatography on silica gel eluting with 3:2 ethyl acetate/hexanes.
AP/P/ 9 8/01 191
APO00826
-24(C) 2-Methyl-2-(5-pyridin-2-ylthiophene-2-sulfonylamino)-N-(2-trimethylsilanylethoxy)propionamide (80 mg, 0.18 mmole) was dissolved in trifiuoroacetic acid and the resulting solution was stirred at room temperature for 16 hours. The trifiuoroacetic acid was evaporated under vacuum, chasing with methanol, to afford N-hydroxy-2-methyl-25 (5-pyridin-2-ylthiophene-2-sulfonylamino)propionamide, a yellow oil (60 mg, 97%) which was crystallized from ethanol. MP 165-166°C. MS: 342 (M+1).
The titled compounds of Examples 14-15 were prepared by a method analogous to that described in Example 13 using the reagent indicated.
Example 14
-(5-Pvridin-2-vl-thiophene-2-sulfonylamino)cvclopentane-1 -carboxylic acid hydroxyamide
-Aminocyciopentane-1 -carboxylic acid; 5-pyridin-2-ylthiophene-2-sulfonyl chloride. MS: 368 (M + 1).
Example 15
-f4-(4-Chiorophenoxv)benzenesuifonvlamino1cyclopropane-1 -carboxylic acid hydroxyamide
-Aminocyclopropane-1 -carboxylic acid; 4-(4-chlorophenoxy)benzenesulfonyl chloride. MS: 381 (M-1).

Claims (8)

1. A compound of the formula
R1
HO·
-NI
H
APO0082fi
-250
II I
-c—c~
H •N
I hi vine now particularly described and a-cviiaineJ mv/our said inventi·? a,.,! d· v hat inn’nk’r the same is to be peribimed bwe de. tare that whal ί/we s. 1.
mu is \// //S\
0 Q or the pharmaceutically acceptable salts thereof, wherein
R1 and R2 are each independently selected from (C,-Ce)alkyl, trifluoromethyl, trifluoromethyl(C,-Ce) alkyl, (C,-Cfl)alkyl(difluoromethylene), (¢,CJalky^drfiuoromethyienelC^CJaJkyi, (Ce-C10)aryf, (C2-C8}heteroaryi, (Ce-C10)aryl(C,Ce)aJkyf, (C2-C9)heteroaryl(C,-Ce)alkyl or R1 and R2 may be taken together to form a (C3Ce)cycfoalkyl or benzo-fused (C3-Ce)cycloalkyf ring or a group of the formula
AP/F. 9 8/01 191 wherein n and m are independently 1 or 2 and X is CF2, S, O or NR3 wherein R3 is hydrogen, (C,-Ce)alkyl, (Ce-C10)aryi, (C2-C9}heteroaryl, (Ce-C,0)aryl(C,-Ce)aJkyl. (C2Cg)heteroaryl(C,-CB)alkyl, {C,-Ce)alkylsulfonyl, (Ce-C10)aryisulfonyl or acyl; and
Qls^,-Ce)alkyl,{Ce-Cw)aryl,(Ce-Ct0)aiyloxy^e-C,0)aryl1(Ce<5w)aryl(Ce^t0)aryl, {Ce-C10)aryl(Ce-C10)aryl(C,-Ce)alkyl, (Ce-C,0)aryi(C2-Ce)heteroary1, (Ce-C10)aryloxy(C2C9)heteroary1, (C2-Ce}heteroaryi, (C2-Ce)heteroaryl(C2-Ce}heteroaryi, (C2-C8)heteroaryl(CeC10)aryi,(^ -Ce)alkyl(Ce-C,0)aryl,{C,-Ce)alkoxy(C6-C,0)aryl.{Ce-C,0)aryl(C,-Ce)alkoxy(CeC10)aryl, {Ce-C10)aryl(C,-C6)aJkoxy(C,-Ce)alky1, (C2-C8)heteroarytoxy{Ce-C10)aryi, (¢,Ce)alkyl(Cz-Ce)heteroaryl, (¢, -Ce)alkoxy(C2-Ce)heteroaryf, (Ce-C, 0)aryl(C,-Ce)alkoxy{C2C9)heteroaryl, (C2-C,)heteroaryloxy(C2-C,)heteroaryl, (Ce-Cw)aryloxy{C,-Ce)alkyl. (C2« C8)heteroaryloxy(C,-C6) alkyl, (C,-Ce)alkyf(Ce-Cw)aryloxy(Ce-C,0)aryl, (C,-Ce}aIkyl(C2C9)heteroaryloxy(Ce-C,0)aryl, (C^CeialkyliCe-C^JaryloxyiCj-CjJheteroaryl, (¢,Ce)alkoxy{Ce-C,0)aryloxy(Ce-Ct0)aryl, (C,-Ce)alkoxy(C2-C9)heteroaryloxy(Ce-C,0)aryl or (C^C^alkoxy(0,,-0,0)aryloxy(Cj-C9)heteroaryl wherein each aryl group is optionally substituted byfluoro, chloro, bromo, (CT-CgJalkyl, (CT-C^alkoxy orperfluoroiC^CjJalkyl.
2. A compound according to claim 1, wherein R’ and R2 are taken together to form a (C3-Ce)cycloalkyl or benzo-fused (C3-C„)cycloalkyl ring or a group of the
5 formula
APOύ0826 wherein n and m are independently 1 or 2 and X is CF2, S, 0 or NR3 wherein R3 is hydrogen, (C^-C^alkyl, (C6-C,0)aryl, (C2-C9)heteroaryl, (Cg-C^aryl^-CJaJkyl, (C2C9)heteroaryl(C,-Ce)alkyl, (C^-C^alkylsulfonyl, (C6-C10)arylsulfonyl or acyl.
3. A compound according to claim 2, wherein R1 and R2 are taken together 15 to form a (C3-Ce)cycloalkyl or benzo-fused (C3-Ce)cycloalkyl ring.
4. A compound according to claim 1, wherein R1 and R2 are each independently (C,-Ce)aikyi.
5. A compound according to any one of claims 1 to 4, wherein Q is (CeC10)aryl, (C6-C10)aryl(Ce-C10)aryl, (Ce-C10)aryioxy(Ce-C10)aryl, (Ce-C10)aryloxy(C220 Cg)heteroaryl, (C2-C9)heteroaryl, (C2-C9)heteroaryl(C2-C9)heteroaryl, (Ce-C10)aryl(C2¥ C9)heteroaryl, (C2-C9)heteroaryl(Ce-C10)aryl or (C2-C9)heteroaryloxy(Ce-C10)aryl.
6. A compound according to claim 5, wherein Q is (Ce-C1o)aryloxy(CeC10)aryl.
7. A compound according to claim 1, wherein said compound is selected 25 from the group consisting of:
3- [4-(4-Fluorophenoxy)benzenesulfonylamino]azetidine-3-carboxylic acid hydroxyamide;
4- [4-(4-Fluorophenoxy)benzenesulfonylamino}piperidine-4-carboxylic acid hydroxyamide;
30 1-[4-(4-Fluorophenoxy)benzenesulfonylamino]cyclopropane-1 -carboxylic acid hydroxyamide;
1-[4-(4-Chlorophenoxy)benzenesulfonylamino]cyclopropane-1 -carboxylic acid hydroxyamide;
ΑΡ/Γ7 98/01191
AP Ο ύ Ο 8 2 6
-271 -[4-(4-Fluorophenoxy)benzenesulfonyiamino]cyclobutane-1 -carboxylic acid hydroxyamide;
1 -[4-(4-Chlorophenoxy)benzenesulfonylamino]cyclobutane-1 -carboxylic acid hydroxyamide;
5 1-[4-(4-FIuorophenoxy)benzenesulfonylamino]cyclopentane-1-carboxylic acid hydroxyamide;
1 -[4-{4-Fluorophenoxy)benzenesutfonylamino]cyclohexane-1 -carboxylic acid hydroxy amide;
2-[4-(4-Fluorophenoxy)benzenesutfonylamino]-N-hydroxy-2-methylpropionamide;
10 2-[4-(4-Chtorophenoxy)benzenesulfonyiamino]-N-hydroxy-2-methyl-propionamide;
N-Hydroxy-2-methyl-2-(5-pyridin-2-yIthiophene-2-suifonylamino)propionamide;
1 -(5-Pyridin-2-yl-thiophene-2-sulfonylamino)cyclopentane-1 -carboxylic acid hydroxy amide;
1 -(4'-Ftuorobiphenyl-4-sulfonylamino)cyclopropane-1 -carboxylic acid
15 hydroxyamide;
1 -(4'-Fluorobiphenyl-4-sulfonylamino)cyclobutane-1 -carboxylic acid hydroxy amide;
1 -(4'-Fluorobiphenyl-4-sulfonylamino)cyclopentane-1 -carboxylic acid hydroxyamide;
20 2-(4-Methoxybenzenesufonylamino)indan-2-carboxy1ic acid hydroxyamide; and
2-[4-(4-Fluorophenoxy)benzenesulfonylamino]-indan-2-carboxylic acid hydroxy amide.
8. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, mucular
25 degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAIDS and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the
30 production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.
APAP/P/1998/001191A 1997-02-03 1998-01-29 Arysulfonylamino hydroxamic acid derivatives. AP826A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3685797P 1997-02-03 1997-02-03

Publications (2)

Publication Number Publication Date
AP9801191A0 AP9801191A0 (en) 1998-03-31
AP826A true AP826A (en) 2000-04-28

Family

ID=21891041

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001191A AP826A (en) 1997-02-03 1998-01-29 Arysulfonylamino hydroxamic acid derivatives.

Country Status (42)

Country Link
US (1) US6303636B1 (en)
EP (1) EP0977733B1 (en)
JP (1) JP3765584B2 (en)
KR (1) KR100317146B1 (en)
CN (1) CN1113862C (en)
AP (1) AP826A (en)
AR (1) AR011101A1 (en)
AT (1) ATE248812T1 (en)
AU (1) AU721748B2 (en)
BG (1) BG64308B1 (en)
BR (1) BR9807815A (en)
CA (1) CA2279276C (en)
CO (1) CO4920234A1 (en)
DE (1) DE69817801T2 (en)
DK (1) DK0977733T3 (en)
DZ (1) DZ2410A1 (en)
EA (1) EA002594B1 (en)
ES (1) ES2202796T3 (en)
GT (1) GT199800025A (en)
HN (1) HN1998000011A (en)
HR (1) HRP980058B1 (en)
HU (1) HUP0000852A2 (en)
ID (1) ID22799A (en)
IL (2) IL131042A (en)
IS (1) IS1950B (en)
MA (1) MA26471A1 (en)
MY (1) MY121754A (en)
NO (1) NO313631B1 (en)
NZ (1) NZ336840A (en)
OA (1) OA11081A (en)
PA (1) PA8445801A1 (en)
PE (1) PE57799A1 (en)
PL (1) PL335027A1 (en)
PT (1) PT977733E (en)
SK (1) SK283963B6 (en)
TN (1) TNSN98019A1 (en)
TR (1) TR199901849T2 (en)
TW (1) TW509668B (en)
UA (1) UA63935C2 (en)
UY (1) UY24866A1 (en)
WO (1) WO1998033768A1 (en)
ZA (1) ZA98823B (en)

Families Citing this family (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298617A1 (en) 1997-07-31 1999-02-11 Yetunde Olabisi Taiwo Acyclic metalloprotease inhibitors
PA8469601A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURE FOR RENTING STERICALLY IMPAIRED SULFONAMIDES
PA8469301A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURES FOR THE PREPARATION OF HYDROXAMIC ACIDS.
GT199900044A (en) * 1998-04-10 2000-09-14 PROCEDURES FOR PREPARING PHENOXYPHENYL SULFONYL HALIDES.
UA59453C2 (en) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. HYDROXYPIPECOLATE HYDROXAMIC ACID DERIVATIVES AS matrix metalloproteinase inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
MXPA01008857A (en) 1999-03-03 2002-07-02 Procter & Gamble Dihetero-substituted metalloprotease inhibitors.
BR0008716A (en) 1999-03-03 2002-09-24 Procter & Gamble Metalloprotease inhibitors containing alkenyl or alkynyl
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
DE60003863T2 (en) 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
PT1181286E (en) 1999-05-28 2004-02-27 Pfizer Prod Inc ACID HYDROXAMIDES 3- (ARYLSULPHONYLAMINO) -TETRAHYDROPYRANE-3-CARBOXYLIC ACID
HN2000000052A (en) * 1999-05-28 2001-02-02 Pfizer Prod Inc HYDROXYAMIDES OF ACIDS 3- (ARYLSULFONYLAMINE) - TETRAHIDROFURAN-3-CARBOXILICOS.
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001070693A2 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
NZ520656A (en) * 2000-03-21 2004-05-28 Procter & Gamble Heterocyclic side chain containing metalloprotease inhibitors
NZ520657A (en) 2000-03-21 2004-11-26 Procter & Gamble Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
JP4975941B2 (en) * 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド (E) -N-hydroxy-3- (3-sulfamoyl-phenyl) acrylamide compound and therapeutic use thereof
EP1348443A4 (en) * 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINATION DRUGS
ME00502B (en) 2001-01-05 2011-10-10 Amgen Fremont Inc Antibodies to insulin-like growth factor i receptor
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
BR0213736A (en) 2001-11-01 2004-10-19 Wyeth Corp allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
WO2003055851A1 (en) * 2001-12-27 2003-07-10 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
DE10206404A1 (en) * 2002-02-14 2003-08-28 Gruenenthal Gmbh Synthesis of substituted sulfonylamines
AU2003206068A1 (en) 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
KR100984595B1 (en) 2002-03-13 2010-09-30 어레이 바이오파마 인크. N3 alkylated benzimidazole derivatives as MEV inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004056806A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
EP1622617A2 (en) * 2003-02-11 2006-02-08 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
DK1603570T5 (en) 2003-02-26 2013-12-09 Sugen Inc AMINOHETEROARYL COMPOUNDS AS PROTEINKINASE INHIBITORS
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
ES2314444T3 (en) 2003-08-29 2009-03-16 Pfizer Inc. TIENOPIRIDINE-PHENYLACETAMIN AND ITS USEFUL DERIVATIVES AS NEW ANTIANGIOGEN AGENTS.
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
CN1905873A (en) 2003-11-19 2007-01-31 阵列生物制药公司 Heterocyclic inhibitors of MEK and methods of use thereof
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
KR20080019733A (en) 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 Combination therapy for non-hematologic malignancies using anti-IGF-1AL antibody
ITFI20040174A1 (en) * 2004-08-03 2004-11-03 Protera S R L ARYTHOLPHONAMIDIC DERIVATIVES OF HYDROXAMIC ACID WITH INHIBITORY ACTION OF METALLOPROTEINASE
DE602005020465D1 (en) 2004-08-26 2010-05-20 Pfizer ENANTIOMERINEINE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITOR
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
ES2405785T3 (en) 2005-05-18 2013-06-03 Array Biopharma Inc. MEK heterocyclic inhibitors and methods of use thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulphate
KR20080104347A (en) * 2006-03-29 2008-12-02 노파르티스 아게 Selective Hydroxamate-Based MPM Inhibitor
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5269762B2 (en) 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Pyridonesulfonamide and pyridonesulfamide as MEK inhibitors
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
KR20090111847A (en) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. MEV inhibitor
CN101678215B (en) 2007-04-18 2014-10-01 辉瑞产品公司 Sulfonamide derivatives for the treatment of abnormal cell growth
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
AU2008259804B2 (en) * 2007-06-05 2013-04-18 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
CA2924436A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
JP5421925B2 (en) 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド 5-Anilinoimidazopyridine and method of use
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (en) 2008-01-04 2010-11-12 Intellikine Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS.
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
BRPI0915231A2 (en) 2008-07-08 2018-06-12 Intellikine Inc kinase inhibitor compounds and methods of use
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
RU2683325C2 (en) 2009-02-05 2019-03-28 Иммьюноджен, Инк. New benzodiazepine derivatives
TW201041892A (en) 2009-02-09 2010-12-01 Supergen Inc Pyrrolopyrimidinyl Axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN102448938A (en) 2009-03-27 2012-05-09 阿迪生物科学公司 Dihydropyridinesulfonamides and Dihydropyridinesulfonamides as MEK Inhibitors
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
JP2013503846A (en) 2009-09-01 2013-02-04 ファイザー・インク Benzimidazole derivatives
CN102666512B (en) 2009-10-13 2014-11-26 奥斯特姆医疗公司 Novel MEK inhibitors, useful in the treatment of diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
KR20130009760A (en) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Cd20 antibodies and uses thereof
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2582727B8 (en) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
FR2962649B1 (en) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers TREATMENT OF A PATHOLOGY RELATED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULFONAMIDE COMPOUND
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
JP2013545749A (en) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
ES2637113T3 (en) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedures for preparing isoquinolinones and solid forms of isoquinolinones
MX2013008833A (en) 2011-02-02 2013-12-06 Amgen Inc METHODS AND COMPOSITIONS RELATED TO THE INHIBITION OF RECEIVER OF THE SIMULAR GROWTH FACTOR TO INSULIN 1 (IGF-1R).
JP5826863B2 (en) 2011-02-15 2015-12-02 イミュノジェン・インコーポレーテッド Cytotoxic benzodiazepine derivatives
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
ES2683902T3 (en) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Benzodiazepine Administration
AR088218A1 (en) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
MX2014002542A (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
EP2758402B9 (en) 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidine and purine derivatives
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2764025B1 (en) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antibodies against hmw-maa
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
WO2013126617A1 (en) 2012-02-22 2013-08-29 The Regents Of The University Of Colorado, A Body Corporate Bouvardin derivatives and therapeutic uses thereof
CN107082779A (en) 2012-03-30 2017-08-22 理森制药股份公司 It is used as the noval chemical compound of C MET protein kinase modulators
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
HK1211208A1 (en) 2012-08-22 2016-05-20 Immunogen, Inc. Cytotoxic benzodiazepine derivative
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6423804B2 (en) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド Complex containing cell binding agent and cytotoxic agent
MX394360B (en) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc JAK2 AND ALK2 INHIBITORS AND METHODS OF THEIR USE.
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2904393A1 (en) 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201602572YA (en) 2013-10-03 2016-04-28 Kura Oncology Inc Inhibitors of erk and methods of use
PT3052485T (en) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CR20160497A (en) 2014-04-30 2016-12-20 Pfizer DERIVATIVES OF DIHETEROCICLO LINKED TO CYCLALKYL
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
JP6811706B2 (en) 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Human monoclonal antibodies against EPHA4 and their use
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
JP2017528498A (en) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Inhibitors of KRAS G12C mutant protein
JP6621477B2 (en) 2014-12-18 2019-12-18 ファイザー・インク Pyrimidine and triazine derivatives and their use as AXL inhibitors
ES2898765T3 (en) 2015-04-10 2022-03-08 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
HK1251655A1 (en) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
KR102608921B1 (en) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. Albocidip prodrug with increased bioavailability
TWI703150B (en) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods and compositions for inhibiting the interaction of menin and mll proteins
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
JP7083497B2 (en) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド Combination therapy for the treatment of cancer
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (en) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 Substituted quinazoline compounds comprising substituted heterocyclic groups and methods for their use
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017132615A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
ES2695533T3 (en) 2016-02-01 2019-01-08 Galderma Res & Dev Benzenesulfonamide compounds, method for their synthesis and use in medicine and cosmetics
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (en) 2016-03-16 2023-07-17 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
ES2910787T3 (en) 2016-05-12 2022-05-13 Univ Michigan Regents ASH1L inhibitors and methods of treatment with them
US11118233B2 (en) 2016-05-18 2021-09-14 The University Of Chicago BTK mutation and ibrutinib resistance
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
CN110366550A (en) 2016-12-22 2019-10-22 美国安进公司 Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer ]pyridazine and pyrido[2,3-d]pyrimidine derivatives
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018137705A1 (en) 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof
JP7327802B2 (en) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー Fused hetero-heterobicyclic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573966A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused n-heterocyclic compounds and methods of use thereof
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869357A (en) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Compounds and methods of use thereof for treating cancer
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
KR20250035037A (en) 2017-09-18 2025-03-11 서트로 바이오파마, 인크. Anti- folate receptor alpha antibody conjugates and their uses
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CN112040947A (en) 2017-12-07 2020-12-04 密歇根大学董事会 NSD family inhibitors and methods of treatment therewith
KR20210003780A (en) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. AXL kinase inhibitors and uses thereof
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3788053B1 (en) 2018-05-04 2024-07-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52564A (en) 2018-05-10 2021-03-17 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
MX2020012204A (en) 2018-06-11 2021-03-31 Amgen Inc KRAS G12C INHIBITORS TO TREAT CANCER.
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
MX2021000887A (en) 2018-08-01 2021-03-31 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer.
JP2022500454A (en) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド Combination therapy with antifolate receptor antibody conjugate
CN113207291A (en) 2018-10-24 2021-08-03 亚瑞克西斯制药公司 2- (2-acryloyl-2, 6-diazaspiro [3.4] oct-6-yl) -6- (1H-indazol-4-yl) benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
AU2019384118B2 (en) 2018-11-19 2025-06-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
JP7686559B2 (en) 2018-12-20 2025-06-02 アムジエン・インコーポレーテツド KIF18A inhibitor
MA54543A (en) 2018-12-20 2022-03-30 Amgen Inc KIF18A INHIBITORS
JP2022513967A (en) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Heteroarylamide useful as a KIF18A inhibitor
KR20260008165A (en) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. Formulations comprising heterocyclic protein kinase inhibitors
MX2021010323A (en) 2019-03-01 2021-12-10 Revolution Medicines Inc Bicyclic heterocyclyl compounds and uses thereof.
MX2021010319A (en) 2019-03-01 2021-12-10 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof.
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
KR20210141621A (en) 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Compositions comprising PKM2 modulators and methods of treatment using same
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
EP4007753B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
EP4007752B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
EP4007756B1 (en) 2019-08-02 2025-12-24 Amgen Inc. Kif18a inhibitors
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
EP4048671B1 (en) 2019-10-24 2026-03-18 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
UA129778C2 (en) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі LOW-MOLECULAR INHIBITORS OF G12C-MUTANT KRAS
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
IL322454A (en) 2019-11-04 2025-09-01 Revolution Medicines Inc Ras inhibitors
TW202132316A (en) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras inhibitors
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
CA3156359A1 (en) 2019-11-08 2021-05-14 Adrian Liam Gill Bicyclic heteroaryl compounds and uses thereof
JP7837865B2 (en) 2019-11-14 2026-03-31 アムジエン・インコーポレーテツド Improved synthesis method for KRAS G12C inhibitor compounds
JP2023501528A (en) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Improved Synthesis of KRAS G12C Inhibitor Compounds
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204333A (en) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin inhibitors and methods of use for treating cancer
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CA3185209A1 (en) 2020-07-10 2021-01-27 Alyssa WINKLER Gas41 inhibitors and methods of use thereof
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
WO2022019920A1 (en) 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
JP7849366B2 (en) 2020-12-22 2026-04-21 キル・レガー・セラピューティクス・インコーポレーテッド SOS1 inhibitors and their use
TW202309022A (en) 2021-04-13 2023-03-01 美商努法倫特公司 Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022232488A1 (en) 2021-04-30 2022-11-03 Celgene Corporation Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
TW202309052A (en) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ras inhibitors
JP2024516450A (en) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド Covalent RAS inhibitors and uses thereof
KR20240017811A (en) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. RAS inhibitors for the treatment of cancer
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
JP2024521399A (en) 2021-06-10 2024-05-31 ニューレリス、インク． Compositions and methods for treating seizure disorders in pediatric patients - Patents.com
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
US20240294548A1 (en) 2021-10-12 2024-09-05 Peloton Therapeutics Inc. Tricyclic sultams and sulfamides as antitumor agents
CN119212994A (en) 2021-12-17 2024-12-27 建新公司 Pyrazolopyrazine compounds as SHP2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
KR20240156373A (en) 2022-03-07 2024-10-29 암젠 인크 Method for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
JP2025510572A (en) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド Methods for treating immunorefractory lung cancer
TW202412755A (en) 2022-04-25 2024-04-01 美商耐斯泰德醫療公司 Mitogen-activated protein kinase (mek) inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CA3259758A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
JP2025521928A (en) 2022-07-08 2025-07-10 ネステッド・セラピューティクス・インコーポレイテッド Mitogen-activated protein kinase (MEK) inhibitors
AU2023358792A1 (en) 2022-10-14 2025-04-17 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (en) 2023-04-07 2025-06-18 Revolution Medicines Inc RAS INHIBITORS
CR20250420A (en) 2023-04-07 2025-11-20 Revolution Medicines Inc MACROCYCLIC RAS INHIBITORS
CN121464140A (en) 2023-04-14 2026-02-03 锐新医药公司 Crystalline forms of RAS inhibitors, compositions containing the same, and methods of use thereof
CN121100123A (en) 2023-04-14 2025-12-09 锐新医药公司 Crystalline forms of Ras inhibitors
CN121889153A (en) 2023-04-24 2026-04-17 耐斯泰德医疗公司 Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK)
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025043187A1 (en) 2023-08-24 2025-02-27 Otsuka Pharmaceutical Co., Ltd. Fixed dose combinations of cedazuridine and azacitidine
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024358957A1 (en) 2023-10-13 2026-04-02 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025090905A1 (en) 2023-10-26 2025-05-01 Nested Therapeutics, Inc. Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
TW202542151A (en) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Sos1 inhibitors and uses thereof
TW202547461A (en) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras inhibitors
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025259841A1 (en) 2024-06-13 2025-12-18 Nested Therapeutics, Inc. Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]jmethyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035750A1 (en) 2024-08-05 2026-02-12 Pivot Therapeutics, Inc. Inhibitors of akt and uses thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026080697A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606046A1 (en) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
WO1996027583A1 (en) * 1995-03-08 1996-09-12 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017645A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
BR9814147A (en) * 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivatives of carboxylic and hydroxamic acid having inhibitory activity of mmp and tnf"
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
EP0952148B1 (en) * 1998-04-10 2004-05-12 Pfizer Products Inc. Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
PA8469501A1 (en) * 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606046A1 (en) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
WO1996027583A1 (en) * 1995-03-08 1996-09-12 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
CO4920234A1 (en) 2000-05-29
OA11081A (en) 2002-03-14
ID22799A (en) 1999-12-09
DE69817801T2 (en) 2004-03-11
ATE248812T1 (en) 2003-09-15
KR20000070721A (en) 2000-11-25
HRP980058B1 (en) 2002-04-30
IL131042A0 (en) 2001-01-28
PA8445801A1 (en) 2000-05-24
NZ336840A (en) 2001-01-26
HK1026203A1 (en) 2000-12-08
EP0977733B1 (en) 2003-09-03
MA26471A1 (en) 2004-12-20
JP2000508350A (en) 2000-07-04
AU721748B2 (en) 2000-07-13
UA63935C2 (en) 2004-02-16
NO993730L (en) 1999-10-01
PT977733E (en) 2003-12-31
IS5129A (en) 1999-07-23
JP3765584B2 (en) 2006-04-12
CA2279276C (en) 2005-09-13
BG103616A (en) 2000-02-29
DZ2410A1 (en) 2003-01-04
PE57799A1 (en) 1999-06-11
CA2279276A1 (en) 1998-08-06
UY24866A1 (en) 2000-09-29
BG64308B1 (en) 2004-09-30
ES2202796T3 (en) 2004-04-01
WO1998033768A1 (en) 1998-08-06
AR011101A1 (en) 2000-08-02
BR9807815A (en) 2000-03-08
TNSN98019A1 (en) 2005-03-15
IL131042A (en) 2004-07-25
SK283963B6 (en) 2004-06-08
DE69817801D1 (en) 2003-10-09
NO993730D0 (en) 1999-08-02
TR199901849T2 (en) 2000-02-21
GT199800025A (en) 1999-07-24
HUP0000852A2 (en) 2001-05-28
EA002594B1 (en) 2002-06-27
DK0977733T3 (en) 2003-11-24
HRP980058A2 (en) 1998-12-31
US6303636B1 (en) 2001-10-16
ZA98823B (en) 1999-08-02
HN1998000011A (en) 1999-02-09
AU8191798A (en) 1998-08-25
MY121754A (en) 2006-02-28
IS1950B (en) 2004-10-13
SK101299A3 (en) 2002-04-04
CN1249743A (en) 2000-04-05
PL335027A1 (en) 2000-03-27
EP0977733A1 (en) 2000-02-09
TW509668B (en) 2002-11-11
KR100317146B1 (en) 2001-12-22
NO313631B1 (en) 2002-11-04
AP9801191A0 (en) 1998-03-31
EA199900604A1 (en) 2000-04-24
CN1113862C (en) 2003-07-09

Similar Documents

Publication Publication Date Title
AP826A (en) Arysulfonylamino hydroxamic acid derivatives.
EP0950059B1 (en) Cyclic sulfone derivatives
AP733A (en) Arylsulfonylamino hydroxamic acid derivatives.
US5861510A (en) Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
EP1003720B1 (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
US6147061A (en) Phosphinate based inhibitors of matrix metalloproteases
EP0966438A1 (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
US20020006920A1 (en) Arylsulfonylamino hydroxamic acid derivatives
US6509337B1 (en) Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
MXPA99007143A (en) Arylsulfonylamino hydroxamic acid derivatives
MXPA99006301A (en) Cyclic sulfone derivatives
CZ267699A3 (en) Derivatives of arylsulfonylaminohydroxamic acid, pharmaceutical preparation, inhibition method of matrix metalloproteinases or production of tumor necrosis factor and treatment method
EP1415984A1 (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives